WallStreetZen

NASDAQ: AGRX
Agile Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for AGRX

Based on 2 analysts offering 12 month price targets for Agile Therapeutics Inc.
Min Forecast
$2.50+292.46%
Avg Forecast
$3.75+488.7%
Max Forecast
$5.00+684.93%

Should I buy or sell AGRX stock?

Based on 2 analysts offering ratings for Agile Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

AGRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 2%
2
BuyMaintains$2.50+292.46%2021-11-03
RBC Capital
Bottom 18%
18
BuyMaintains$5.00+684.93%2021-07-27
Anonymous
HC Wainwright & Co.
BuyMaintains$7.00+998.90%2020-12-08

1 of 1

Forecast return on equity

Is AGRX forecast to generate an efficient return?
Company
45.47%
Industry
91.05%
Market
37.5%
AGRX's Return on Equity is forecast to be high in 3 years (45.47%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is AGRX forecast to generate an efficient return on assets?
Company
13.24%
Industry
76.61%
AGRX is forecast to generate lower Return on Assets (13.24%) than the US Drug Manufacturers - Specialty & Generic industry average (76.61%)
Forecast

AGRX earnings per share forecast

What is AGRX's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.78+0%
Avg 2 year Forecast
-$0.58-25.64%
Avg 3 year Forecast
-$0.27-65.38%

AGRX revenue forecast

What is AGRX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$4.4M+30.9%
Avg 2 year Forecast
$22.6M+577.05%
Avg 3 year Forecast
$73.2M+2,092.39%
AGRX's revenue is forecast to grow at an exceptional rate of 170.02% per year
Forecast

AGRX revenue growth forecast

How is AGRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
170.02%
Industry
24.29%
Market
10.08%
AGRX's revenues are forecast to grow faster (170.02% per year) than the US Drug Manufacturers - Specialty & Generic industry average (24.29%)
Forecast
AGRX's revenues are forecast to grow faster (170.02% per year) than the US market average (10.08%)
Forecast

Agile Therapeutics Stock Forecast FAQ

Is Agile Therapeutics Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AGRX) stock is to Buy AGRX stock.

Out of 2 analysts, 0 (0%) are recommending AGRX as a Strong Buy, 2 (100%) are recommending AGRX as a Buy, 0 (0%) are recommending AGRX as a Hold, 0 (0%) are recommending AGRX as a Sell, and 0 (0%) are recommending AGRX as a Strong Sell.

What is AGRX's earnings growth forecast for 2021-2023?

(NASDAQ: AGRX) Agile Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 27.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Agile Therapeutics's earnings in 2021 is -$69,157,000.On average, 3 Wall Street analysts forecast AGRX's earnings for 2021 to be $-94,688,906, with the lowest AGRX earnings forecast at $-105,614,549, and the highest AGRX earnings forecast at $-83,763,263. On average, 3 Wall Street analysts forecast AGRX's earnings for 2022 to be $-70,409,699, with the lowest AGRX earnings forecast at $-112,898,311, and the highest AGRX earnings forecast at $-47,344,453.

In 2023, AGRX is forecast to generate $-32,776,929 in earnings, with the lowest earnings forecast at $-37,632,770 and the highest earnings forecast at $-27,921,088.

What is AGRX's revenue growth forecast for 2021-2023?

(NASDAQ: AGRX) Agile Therapeutics's forecast annual revenue growth rate of 170.02% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 24.29%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Agile Therapeutics's revenue in 2021 is $3,337,000.On average, 3 Wall Street analysts forecast AGRX's revenue for 2021 to be $530,257,872, with the lowest AGRX revenue forecast at $522,002,942, and the highest AGRX revenue forecast at $534,870,921. On average, 3 Wall Street analysts forecast AGRX's revenue for 2022 to be $2,742,700,574, with the lowest AGRX revenue forecast at $2,501,972,240, and the highest AGRX revenue forecast at $3,107,738,445.

In 2023, AGRX is forecast to generate $8,881,333,774 in revenue, with the lowest revenue forecast at $5,623,064,249 and the highest revenue forecast at $12,139,603,300.

What is AGRX's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: AGRX) forecast ROA is 13.24%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 76.61%.

What is AGRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AGRX price target, the average AGRX price target is $3.75, with the highest AGRX stock price forecast at $5.00 and the lowest AGRX stock price forecast at $2.50.

On average, Wall Street analysts predict that Agile Therapeutics's share price could stay at $3.75 by Nov 3, 2022. The average Agile Therapeutics stock price prediction forecasts a potential downside of N/A from the current AGRX share price of $0.64.

What is AGRX's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: AGRX) Agile Therapeutics's current Earnings Per Share (EPS) is -$0.78. On average, analysts forecast that AGRX's EPS will be $-0.78 for 2021, with the lowest EPS forecast at $-0.87, and the highest EPS forecast at $-0.69. On average, analysts forecast that AGRX's EPS will be $-0.58 for 2022, with the lowest EPS forecast at $-0.93, and the highest EPS forecast at $-0.39. In 2023, AGRX's EPS is forecast to hit $-0.27 (min: $-0.31, max: $-0.23).

What is AGRX's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: AGRX) forecast ROE is 45.47%, which is considered strong.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.